Non-steroidal Anti-inflammatory Drugs Market to Witness a Pronounce Growth During 2022 – 2030: Grand View Research Inc.

 Non-steroidal Anti-inflammatory Drugs Market Growth & Trends

The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030, expanding at a CAGR of 5.36% during the forecast period, according to a new report by Grand View Research, Inc. Nonsteroidal anti-inflammatory drugs are drugs that are primarily used to relieve inflammation and pain, as well as to lower elevated body temperature. The high prescription rate of non-steroidal anti-inflammatory drugs (NSAIDs) for relief of symptoms of painful periods, headaches, fever, arthritis, sprains, strains, and other types of chronic pain is expected to drive the market during the forecast period.

The non-steroidal anti-inflammatory drugs market is expected to witness growth opportunities owing to factors such as the rising prevalence of targeted diseases and chronic pain across the globe, coupled with the high prevalence of these diseases in the geriatric population. Moreover, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs for headaches, migraines, and menstrual pain are also expected to boost the growth during the forecast period. 

Non-steroidal Anti-inflammatory Drugs Market Report Scope

Report Attribute	Details
Market size value in 2022	USD 20,486.56 million
Revenue forecast in 2030	USD 31,287.73 million
Growth rate	CAGR of 5.36% from 2022 to 2030
Base year for estimation	2021
Historical data	2018 - 2020
Forecast period	2022 - 2030

Moreover, the increasing prevalence of arthritis and other pain-related disorders is also expected to support the growth. For instance, the prevalence of osteoarthritis is higher in the UK, France, and Germany compared to other countries in the Europe region. The prevalence of arthritis is seen to be lower in people who are often engaged in physical activities, and its prevalence rises with age. Thus, the rising prevalence of arthritis is also expected to cater to the growth during the forecast period.

Key market players are adopting strategic initiatives such as geographical expansion and the introduction of combination non-steroidal anti-inflammatory drugs to increase their market share across the globe. For instance, Alkem Labs and Dr. Reddy’s Laboratories Ltd have launched their non-steroidal anti-inflammatory drugs in the U.S. Moreover, increasing approval of OTC drugs for pain management and other inflammatory diseases is expected to drive growth during the forecast period. Thus, owing to the various strategies adopted by key players, the market is likely to boost its growth.

Governments in various regions are undertaking favorable initiatives to reduce the burden of migraine, arthritis, and other diseases in their countries. For instance, the National Institutes of Health has initiated HEAL to accelerate research activities to improve the management of pain and inflammatory diseases. Moreover, the Patient-Centered Outcomes Research Institute has undertaken initiatives to introduce non-opioid treatment options for pain. Such initiatives are expected to increase growth during the forecast period. 

Request a free sample copy or view report summary: Non-steroidal Anti-inflammatory Drugs Market Report

Non-steroidal Anti-inflammatory Drugs Market Report Highlights

• In 2021, the arthritis segment dominated the NSAIDs market owing to the higher prevalence of arthritis across the globe
• The retail pharmacy segment held the largest share and is anticipated to maintain its dominance during the forecast period
• Asia Pacific region is expected to witness the highest CAGR during the forecast period owing to factors such as the high prevalence of pain and related disorders, the high pool of patients, and a rising geriatric population across the region
• North America dominated the market in 2021 due to the higher prevalence of arthritis, the presence of leading market players, and increased research activities within the region

Access Press Release@ https://www.grandviewresearch.com/press-release/global-non-steroidal-anti-inflammatory-drugs-market

Non-steroidal Anti-inflammatory Drugs Market Segmentation

Grand View Research has segmented the non-steroidal anti-inflammatory drugs market based on disease indication, route of administration, distribution channel, and region:

Non-steroidal Anti-inflammatory Drugs Disease Indication Outlook (Revenue, USD Million; 2018 - 2030)

• Arthritis
• Migraine
• Ophthalmic Diseases
• Others

Non-steroidal Anti-inflammatory Drugs Route of Administration Outlook (Revenue, USD Million; 2018 - 2030)

• Oral
• Topical
• Others

Non-steroidal Anti-inflammatory Drugs Distribution Channel Outlook (Revenue, USD Million; 2018 - 2030)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Non-steroidal Anti-inflammatory Drugs Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE

List of Key Players of Non-steroidal Anti-inflammatory Drugs Market

• Pfizer Inc.
• Bayer AG
• GSK plc
• Reddy’s Laboratories Ltd
• Viatris Inc
• Teva Pharmaceutical Industries Ltd.
• Johnson And Johnson Services, Inc.
• Merck & Co., Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.